Cargando...

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

INTRODUCTION: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% of patients obtaining complete hematologic respo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2899790/
https://ncbi.nlm.nih.gov/pubmed/20694077
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!